about
Using electronic medical record data to report laboratory adverse events.A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group.Complications preceding early deaths in Black and White children with acute myeloid leukemia.The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia.Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database.Maternal Pre-pregnancy Body Mass Index and Autism Spectrum Disorder among Offspring: A Population-Based Case-Control Study.Creation of a pediatric mature B-cell non-Hodgkin lymphoma cohort within the Pediatric Health Information System Database.Identifying patient- and family-centered outcomes relevant to inpatient versus at-home management of neutropenia in children with acute myeloid leukemia.Nutritional risk factors predict severe acute graft-versus-host disease and early mortality in pediatric allogeneic hematopoietic stem cell transplantation.Response to Letter Re: Maternal Pre-Pregnancy Body Mass Index and Autism Spectrum Disorder in the Offspring.Opioid utilization among pediatric patients treated for newly diagnosed acute myeloid leukemia.Assisted Reproductive Technology and Birth Defects: Effects of Subfertility and Multiple BirthsEffect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group
P50
Q31158675-B0FAD2EF-C181-4550-B748-754A367F37F0Q36984687-EAF5A679-E438-4AAB-A95D-130CED678EADQ38654476-991B1E07-E43F-4F02-B740-3108B14A42A3Q39175238-5FC2BCA3-D3D7-4A5B-8C4D-9BF46F8B1ABFQ40075349-F54AC493-DD36-4BD1-9934-CDA44E9F6458Q40729012-0A976287-E000-4CC9-95C0-6E62CB30A30DQ47144730-34642A3F-A2C2-4598-98CB-A6EC2619DDC0Q47650171-1648BAFC-5EE6-4F45-B9D3-601A7786AD31Q47697648-746905A8-4FB6-4413-8BA1-967A2A4EE489Q48201924-E536A01D-4AB5-47DA-91D3-DEA8E1147C9DQ50114415-8B7F215C-23F9-4EF1-95FA-5A9E41D650DAQ88354475-D0C8CCBF-6D16-4528-8ADC-01DF011ED308Q94445409-22E73D4B-6CCA-441C-87CE-ADA38894D7BA
P50
description
researcher
@en
wetenschapper
@nl
name
Kelly D Getz
@en
Kelly D Getz
@nl
type
label
Kelly D Getz
@en
Kelly D Getz
@nl
prefLabel
Kelly D Getz
@en
Kelly D Getz
@nl
P31
P496
0000-0003-2020-5153